Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy

24 May 2023

Abstract excerpt

BACKGROUND: Immunotherapy has emerged as an efficient therapeutic approach for cancer management. However, stimulation of host immune system against cancer cells often fails to achieve promising clinical outcomes mainly owing to the immunosuppressive characteristics of the tumor microenvironment (TME). Combination therapeutics that can trigger sustained immunogenic cell death (ICD) have provided new opportunities...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Research and Treatments
Share to Healthcare and Venom Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37226233
DOI: 10.1186/s12916-023-02901-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapyPMID 37226233Read ↗

The oncolytic virus ΔPK has multimodal anti-tumor activity.Semantic proximity Read ↗

Oncolytic Virotherapy: From Bench to BedsideSemantic proximity Read ↗

Oncolytic virotherapy for cancer treatment: challenges and solutionsSemantic proximity Read ↗

Evolution of Oncolytic Viruses: Novel Strategies for Cancer TreatmentSemantic proximity Read ↗

Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and ChallengesSemantic proximity Read ↗

Chimerization of the Anti-Viral CD8+ T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic VirotherapySemantic proximity Read ↗

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus ImmunotherapySemantic proximity Read ↗

Elucidating Mechanisms of Antitumor Immunity Mediated by Live Oncolytic Vaccinia and Heat-Inactivated VacciniaSemantic proximity Read ↗

Employing RNA viruses to fight cancer: novel insights into oncolytic virotherapySemantic proximity Read ↗

Oncolytic virotherapy: the questions and the promiseSemantic proximity Read ↗

Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patientsSemantic proximity Read ↗

Equipping Cancer Cell Membrane Vesicles with Functional DNA as a Targeted Vaccine for Cancer ImmunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.